Photobiomodulation for Management of Temporomandibular Disorder Pain (ULLTRA)
Pain Related to TMD
About this trial
This is an interventional treatment trial for Pain Related to TMD
Eligibility Criteria
Inclusion Criteria: Male or female, aged 18 years and older Meets the CATI pre-screening criteria during pre-screening visit [participant-reported facial pain for at least 3 months and an average pain intensity rating for the week preceding CATI of ≥30 on a numerical rating scale (NRS, 0-100)]. Willing to provide signed and dated informed consent Willing to to comply with all study procedures and to be available for the duration of the study Meets diagnostic criteria for TMD (Masticatory Muscle disorder, 1 A: Myalgia) during Visit 0 Completes a minimum of 4 of 7 daily symptom diary (DSD) entries prior to Visit 1 (Randomization visit), and the weekly average pain score on this DSD is ≥30 of 100 Exclusion Criteria: Active rheumatologic disease Has a medical condition, laboratory finding, or physical exam finding (e.g., renal failure or dialysis, uncontrolled diabetes mellitus, hyperthyroidism, fibromyalgia, or uncontrolled seizures) that precludes participation as determined by the investigator Initiated occlusal appliance therapy within 30 days prior to CATI Initiated non-pharmacologic therapy, such as acupuncture, biofeedback, and/or TENS within 30 days prior to CATI Is in active orthodontic treatment Received any injection therapy (e.g., tender or trigger point injections, steroid injections) for the management of pain within 14 days prior to the CATI Has a history of facial trauma or orofacial surgery within 6 weeks prior to CATI Has a history of psychiatric hospitalization within one year prior to CATI Currently pregnant or lactating Has a known hypersensitivity to laser therapy Currently being treated with chemotherapy or radiation therapy Is undergoing treatment with another investigational drug or treatment initiated within 30 days prior to the Screening and Baseline Visit Initiated a new daily prescribed or over-the counter medication for the management of pain within 30 days prior to Screening and Baseline Visit. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study as determined by the investigator
Sites / Locations
- University of Florida
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Experimental: Active PBM
Sham PBM
PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.